2-amino-5-ethoxycarbonyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-amino-5-ethoxycarbonyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine
• 英文别名: 2-amino-6,7-dihydro-4H-thiazolo[5,4-c]pyridine-5-carboxylic acid ethyl ester；ethyl 2-amino-6,7-dihydrothiazolo[5,4-c]pyridine-5(4H)-carboxylate；ethyl 2-amino-6,7-dihydro-4H-[1,3]thiazolo[5,4-c]pyridine-5-carboxylate
• 化学式: C₉H₁₃N₃O₂S
• 分子量: 227.287
• InChiKey: JCPVTENIUKDOIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.24
• 重原子数：
  15.0
• 可旋转键数：
  1.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  68.45
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  2-amino-5-ethoxycarbonyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine 生成 4,5,6,7-四氢噻唑[5,4-C]吡啶-2-胺
  参考文献：
  名称：

  摘要：

  DOI：
• 作为产物：
  描述：

  氰胺 、 N-乙氧羰基-4-哌啶酮 在 四氢吡咯 、 sulfur 作用下， 以 异丙醇 为溶剂， 反应 8.0h， 以73%的产率得到2-amino-5-ethoxycarbonyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine
  参考文献：
  名称：

  Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation

  摘要：

  Glucokinase (GK) activators are being developed for the treatment of type 2 diabetes mellitus (T2DM). However, existing GK activators have risks of hypoglycemia caused by over-activation of GK in islet cells and dyslipidemia caused by over-activation of intrahepatic GK. In the effort to mitigate risks of hypoglycemia and dyslipidemia while maintaining the promising efficacy of GK activator, we investigated a series of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific partial GK activators, which led to the identification of compound 72 that showed a good balance between in vitro potency and enzyme kinetic parameters, and protected beta-cells from streptozotocin-induced apoptosis. Chronic treatment of compound 72 demonstrated its potent activity in regulation of glucose homeostasis and low risk of dyslipidemia with diabetic db/db mice in oral glucose tolerance test (OGTT). Moreover, acute treatment of compound 72 did not induce hypoglycemia in C57BL/6J mice even at 200 mg/kg via oral administration. (C) 2017 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2017.07.051

文献信息

• NOVEL FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES
  申请人：Srivastava Sanjay

  公开号：US20110130414A1

  公开（公告）日：2011-06-02

  The present invention relates to novel compounds, their pharmaceutically acceptable salts, and their isomers, stereoisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses pharmaceutically acceptable compositions of said compounds and process for preparing novel compounds. The invention further relates to the use of the above-mentioned compounds for the preparation of medicament for use as pharmaceuticals.

  本发明涉及新化合物、其药学上可接受的盐以及其同分异构体、立体异构体、构象异构体、互变异构体、多晶型、水合物和溶剂合物。本发明还涵盖了上述化合物的药学上可接受的组合物以及制备新化合物的方法。该发明还涉及上述化合物用于制备用作药物的药物的用途。
• [EN] FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES<br/>[FR] PYRIMIDINONES THIAZOLO ET OXAZOLO FUSIONNÉES
  申请人：TORRENT PHARMACEUTICALS LTD

  公开号：WO2011045811A1

  公开（公告）日：2011-04-21

  The present invention relates to novel compounds, their pharmaceutically acceptable salts, and their isomers, steroisomers, conformers, tautomers, polymorphs, hydrates and solvates. The present invention also encompasses pharmaceutically acceptable compositions of said compounds and process for preparing novel compounds. The invention further relates to the use of the above-mentioned compounds for the preparation of medicament for use as pharmaceuticals.

  本发明涉及新化合物，其药用盐及其异构体、立体异构体、构象异构体、互变异构体、多型体、水合物和溶剂合物。本发明还涵盖了所述化合物的药用组合物和制备新化合物的方法。该发明还涉及上述化合物用于制备药物用作药物的用途。
• [EN] N-SUBSTITUTED-3,5-DISUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF<br/>[FR] COMPOSÉ BENZAMIDE N-SUBSTITUÉ-3,5-DISUBSTITUÉ ET SES PROCÉDÉ DE PRÉPARATION ET APPLICATION<br/>[ZH] N-取代-3,5-二取代苯甲酰胺类化合物及其制备方法和应用
  申请人：SHANGHAI INST MATERIA MEDICA

  公开号：WO2016112863A1

  公开（公告）日：2016-07-21

  本发明公开一种N-取代-3,5-二取代苯甲酰胺类化合物及其制备方法和应用，该化合物结构如通式I所示，式中，m、X、Y、R1、R2和R3如权利要求书和说明书所示。本发明还公开了包含通式I所示化合的药物组合物。本发明的化合物可以作为葡萄糖激酶激动剂，用于预防和/或治疗与葡萄糖代谢异常相关的疾病。
• ——
  作者：MORSDORF P.、 SCHICKANEDER H.、 ENGLER H.、 AHRENS K. H.

  DOI：——

  日期：——
• FUSED THIAZOLO AND OXAZOLO PYRIMIDINONES
  申请人：Torrent Pharmaceuticals Limited

  公开号：EP2385948A1

  公开（公告）日：2011-11-16